These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31737505)

  • 41. Therapy insight: Potential of statins for cancer chemoprevention and therapy.
    Katz MS
    Nat Clin Pract Oncol; 2005 Feb; 2(2):82-9. PubMed ID: 16264880
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis.
    Wong WW; Dimitroulakos J; Minden MD; Penn LZ
    Leukemia; 2002 Apr; 16(4):508-19. PubMed ID: 11960327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statins Perturb G
    Tennakoon M; Kankanamge D; Senarath K; Fasih Z; Karunarathne A
    Mol Pharmacol; 2019 Apr; 95(4):361-375. PubMed ID: 30765461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.
    Denoyelle C; Vasse M; Körner M; Mishal Z; Ganné F; Vannier JP; Soria J; Soria C
    Carcinogenesis; 2001 Aug; 22(8):1139-48. PubMed ID: 11470741
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-cancer therapy: targeting the mevalonate pathway.
    Swanson KM; Hohl RJ
    Curr Cancer Drug Targets; 2006 Feb; 6(1):15-37. PubMed ID: 16475974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mevalonate Pathway and Human Cancers.
    Bathaie SZ; Ashrafi M; Azizian M; Tamanoi F
    Curr Mol Pharmacol; 2017; 10(2):77-85. PubMed ID: 26758953
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting tumor cell metabolism with statins.
    Clendening JW; Penn LZ
    Oncogene; 2012 Nov; 31(48):4967-78. PubMed ID: 22310279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma.
    Ogura S; Yoshida Y; Kurahashi T; Egawa M; Furuta K; Kiso S; Kamada Y; Hikita H; Eguchi H; Ogita H; Doki Y; Mori M; Tatsumi T; Takehara T
    Oncotarget; 2018 Apr; 9(30):21022-21035. PubMed ID: 29765517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statin-Associated Autoimmune Myopathy: Current Perspectives.
    Tiniakou E
    Ther Clin Risk Manag; 2020; 16():483-492. PubMed ID: 32581543
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis.
    Arnaud C; Veillard NR; Mach F
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Apr; 5(2):127-34. PubMed ID: 15853754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis.
    Nagashima T; Okazaki H; Yudoh K; Matsuno H; Minota S
    Arthritis Rheum; 2006 Feb; 54(2):579-86. PubMed ID: 16447234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statins and endocrine resistance in breast cancer.
    Hyder T; Marti JLG; Nasrazadani A; Brufsky AM
    Cancer Drug Resist; 2021; 4(2):356-364. PubMed ID: 35582035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of different types of statins on proliferation and migration of HGF-induced Human Umbilical Vein Endothelial Cells (HUVECs).
    Burgazli KM; Bui KL; Mericliler M; Albayrak AT; Parahuleva M; Erdogan A
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2874-83. PubMed ID: 24254555
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Developmental processes regulated by the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway: highlights from animal studies.
    Eisa-Beygi S; Ekker M; Moon TW; Macdonald RL; Wen XY
    Reprod Toxicol; 2014 Jul; 46():115-20. PubMed ID: 24732207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
    Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
    Biochem Biophys Res Commun; 2008 Sep; 374(2):309-14. PubMed ID: 18625202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
    Lipkin SM; Chao EC; Moreno V; Rozek LS; Rennert H; Pinchev M; Dizon D; Rennert G; Kopelovich L; Gruber SB
    Cancer Prev Res (Phila); 2010 May; 3(5):597-603. PubMed ID: 20403997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.
    Ishikawa T; Hosaka YZ; Beckwitt C; Wells A; Oltvai ZN; Warita K
    Oncotarget; 2018 Jun; 9(50):29304-29315. PubMed ID: 30034619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
    Wong WW; Tan MM; Xia Z; Dimitroulakos J; Minden MD; Penn LZ
    Clin Cancer Res; 2001 Jul; 7(7):2067-75. PubMed ID: 11448925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression.
    Li R; Gan YH
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of statins on FGF-2-stimulated human umbilical vein endothelial cells.
    Burgazli KM; Behrendt MA; Mericliler M; Chasan R; Parahuleva M; Erdogan A
    Postgrad Med; 2014 Jan; 126(1):118-28. PubMed ID: 24393759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.